Differentiating Tuberculous and Pyogenic Spondylodiscitis: Part I—Epidemiology, Clinical Features, Laboratory Markers, and Tissue-Based Diagnosis
Diagnostics · 17.07.2026 · 16 (14) · 2243
DOI: 10.3390/diagnostics16142243 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 17.07.2026. Verfasst von Anamaria Marian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Romania's National Recovery and Resilience Plan grant of the Romanian Ministry of Investment and European Projects, Romanian Ministry of Investment and European Projects.
Abstract (Originalsprache)
Distinguishing tuberculous spondylodiscitis (TS) from pyogenic spondylodiscitis (PS) remains difficult when presentation is non-specific, blood cultures are negative, or initial biopsy is non-diagnostic. The two entities differ substantially in antimicrobial strategies, resistance testing requirements, public health interventions, and surgical thresholds, yet diagnostic delay is associated with neurological deficits, spinal instability, and permanent deformity. This narrative review maps the non-imaging evidence most useful for frontline differentiation between TS and PS across five domains: epidemiology and risk stratification, clinical presentation, laboratory markers, tissue acquisition and histopathology, and molecular diagnostics. PubMed/MEDLINE was searched from inception to 31 March 2026 using pre-specified Boolean search terms; a secondary Scopus search identified no additional eligible records. Following screening, approximately 90 records were included in this synthesis. Priority was given to comparative TS-versus-PS cohorts, biopsy-yield and culture-negative studies, pathology series, pediatric data, and recent molecular diagnostics literature. Epidemiological TB (tuberculosis) risk, longer symptom duration, constitutional symptoms, deformity, and a less intense acute-phase response increase the probability of TS, whereas healthcare exposure, bacteraemia, recent spinal procedures, and brisk neutrophilic inflammation favor PS. In stable patients, the highest-yield strategy is early blood cultures followed by image-guided biopsy with parallel tissue allocation for bacterial culture, mycobacterial studies, histopathology, and selected molecular assays. No single laboratory marker reliably distinguishes TS from PS without tissue confirmation. Per a 2023 systematic review and meta-analysis, image-guided percutaneous biopsy achieves microbiological confirmation in approximately one-third of cases. Histopathology demonstrating caseating granulomatous inflammation supports TS, although a substantial minority of confirmed cases lack classic features. Supported by cohort prospective data, Xpert MTB/RIF Ultra has the clearest first-line molecular role when TS is plausible and should be requested at the time of first biopsy rather than reserved for salvage testing; broader or targeted next-generation sequencing is best reserved for selected unresolved cases. Imaging differentiation is addressed in the companion manuscript, Part II.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
- Emergency Clinical County Hospital, 400012 Cluj-Napoca, Romania.
- Department of Neurology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
- Department of Medical Genetics, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
- Nicolae Testemiţanu Internal Medicine Department, State University of Medicine and Pharmacy, 2004 Chișinău, Moldova.
- Department of Medical Specialties, Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
ORCID-Profile: Anamaria Marian, Oana Maria Vanța, Larisa Rotaru, Rodica Ungur, Simona Rednic
Förderung
- Romania's National Recovery and Resilience Plan grant of the Romanian Ministry of Investment and European Projects
- Romanian Ministry of Investment and European Projects
Zitieren
APA
Marian, A., Vanța, O. M., Danci, V., Rotaru, L., Tămaș, M. M., Ungur, R., Rednic, S., & Pamfil, C. (2026). Differentiating Tuberculous and Pyogenic Spondylodiscitis: Part I—Epidemiology, Clinical Features, Laboratory Markers, and Tissue-Based Diagnosis. Diagnostics, 16(14), 2243. https://doi.org/10.3390/diagnostics16142243
Vancouver
Marian A, Vanța OM, Danci V, Rotaru L, Tămaș MM, Ungur R, et al. Differentiating Tuberculous and Pyogenic Spondylodiscitis: Part I—Epidemiology, Clinical Features, Laboratory Markers, and Tissue-Based Diagnosis. Diagnostics. 2026;16(14):2243. doi:10.3390/diagnostics16142243
BibTeX
@article{Marian2026,
author = {Marian, Anamaria and Vanța, Oana Maria and Danci, Valentin and Rotaru, Larisa and Tămaș, Maria-Magdalena and Ungur, Rodica and Rednic, Simona and Pamfil, Cristina},
title = {Differentiating Tuberculous and Pyogenic Spondylodiscitis: Part I—Epidemiology, Clinical Features, Laboratory Markers, and Tissue-Based Diagnosis},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {14},
pages = {2243},
doi = {10.3390/diagnostics16142243}
}
EUVIMED